Plus Therapeutics (NASDAQ:CNSY) Stock Rating Cut to Strong Sell at Zacks Research

Plus Therapeutics (NASDAQ:CNSY) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Wednesday, Zacks reports.

Separately, Weiss Ratings started coverage on Plus Therapeutics in a report on Tuesday, August 4th. They issued a “sell (e+)” rating on the stock. Two investment analysts have rated the stock with a Sell rating. Based on data from MarketBeat, Plus Therapeutics currently has an average rating of “Sell”.

Plus Therapeutics Trading Up 11.2%

Shares of CNSY stock opened at $1.88 on Wednesday. The stock’s 50-day moving average price is $2.50. Plus Therapeutics has a 12 month low of $1.49 and a 12 month high of $18.89.

Plus Therapeutics (NASDAQ:CNSY) last posted its earnings results on Friday, August 14th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.35). The firm had revenue of $0.41 million during the quarter. Plus Therapeutics had a negative net margin of 620.70% and a negative return on equity of 394.17%. On average, research analysts anticipate that Plus Therapeutics will post -4.40 EPS for the current fiscal year.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s lead investigational product is RNL, also known as rhenium-186 nanoliposome, an experimental treatment designed to deliver radiation directly to tumors while limiting exposure to surrounding healthy tissue.

Plus Therapeutics is primarily evaluating RNL in cancers of the central nervous system, including recurrent glioblastoma and leptomeningeal metastases.